Fidelity MSCI Health Care Index ETF Analysis: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $81.28, indicating a potential upside of 15.88% from its current trading price of $70.14.
Notable Holdings with Upside Potential: Key underlying holdings of FHLC, such as Xeris Biopharma Holdings (XERS), Mineralys Therapeutics (MLYS), and iRadimed Corp (IRMD), show significant upside potential based on analyst target prices, with XERS at 38.16% higher, MLYS at 21.59%, and IRMD at 17.06%.
Analyst Target Price Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets relative to current prices could lead to potential downgrades if they are based on outdated information.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analysts' targets in light of recent developments in the companies and the healthcare industry.
Wall Street analysts forecast IRMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRMD is 99.00 USD with a low forecast of 98.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast IRMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRMD is 99.00 USD with a low forecast of 98.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 103.890
Low
98.00
Averages
99.00
High
100.00
Current: 103.890
Low
98.00
Averages
99.00
High
100.00
Roth Capital
Buy
maintain
$90 -> $98
2025-11-04
Reason
Roth Capital
Price Target
$90 -> $98
AI Analysis
2025-11-04
maintain
Buy
Reason
Roth Capital raised the firm's price target on iRadimed to $98 from $90 and keeps a Buy rating on the shares after its Q3 earnings beat. Legacy pump sales remain strong despite the planned full launch of the next generation version in Q1, monitor sales accelerated in the quarter, and there could be nice uplift from the cross-selling the next gen pump into non-user hospitals, the analyst tells investors in a research note.
Lake Street
Buy
maintain
$75 -> $100
2025-11-03
Reason
Lake Street
Price Target
$75 -> $100
2025-11-03
maintain
Buy
Reason
Lake Street raised the firm's price target on iRadimed to $100 from $75 and keeps a Buy rating on the shares after a top and bottom line beat with revenue and EPS guidance increased in Q3. While acknowledging that shares trade at a premium valuation, the firm sees a record backlog providing near-term visibility and the new 3870 IV Pump launch driving growth acceleration in 2026, the analyst tells investors.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IRMD
Unlock Now
Roth Capital
Kyle Bauser
Buy
maintain
$90 -> $98
2025-11-03
Reason
Roth Capital
Kyle Bauser
Price Target
$90 -> $98
2025-11-03
maintain
Buy
Reason
Roth Capital analyst Kyle Bauser raised the firm's price target on iRadimed to $98 from $90 and keeps a Buy rating on the shares, citing higher forward estimates and confidence in the business after the company reported Q3 sales and EPS above the firm's and consensus estimates and raised full-year guidance.
Roth Capital
Kyle Bauser
initiated
$90
2025-10-31
Reason
Roth Capital
Kyle Bauser
Price Target
$90
2025-10-31
initiated
Reason
Roth Capital analyst Kyle Bauser resumed coverage of iRadimed with a Buy rating and $90 price target. The firm expects the company to benefit from the launch of its next-gen non-magnetic IV infusion pump. The pump has "significant enhancements" and a premium selling price versus the older version, the analyst tells investors in a research note.
About IRMD
IRadimed Corporation develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and accessories and services. Its MRidium 3860+ MRI Compatible IV infusion pump system provides a non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to deliver anesthesia safely and predictably and other IV medications or fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to monitor a patient’s vital signs safely and accurately during various MRI procedures. The Company sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
